BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30575642)

  • 1. Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
    Hu Z; Ni P; Fan X; Men R; Yang L
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):277. PubMed ID: 30575642
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
    Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
    Lindor K
    N Engl J Med; 2007 Oct; 357(15):1524-9. PubMed ID: 17928600
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.
    Zhang H; Yang J; Zhu R; Zheng Y; Zhou Y; Dai W; Wang F; Chen K; Li J; Wang C; Li S; Liu T; Abudumijiti H; Zhou Z; Wang J; Lu W; Wang J; Xia Y; Zhou Y; Lu J; Guo C
    Drug Des Devel Ther; 2015; 9():567-74. PubMed ID: 25632224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom.
    Corpechot C; Poupon R
    Hepatology; 2007 Oct; 46(4):963-5. PubMed ID: 17894325
    [No Abstract]   [Full Text] [Related]  

  • 6. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis.
    Vítek L; Zelenková M; Brůha R
    Dig Liver Dis; 2010 Dec; 42(12):911-2. PubMed ID: 20619755
    [No Abstract]   [Full Text] [Related]  

  • 7. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
    Treiber G; Malfertheiner P
    J Clin Gastroenterol; 2005 Oct; 39(9):837-8; author reply 838. PubMed ID: 16145353
    [No Abstract]   [Full Text] [Related]  

  • 8. Ursodeoxycholic acid for primary biliary cirrhosis.
    Gluud C; Christensen E
    Cochrane Database Syst Rev; 2002; (1):CD000551. PubMed ID: 11869580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
    Levy C
    Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid.
    Corpechot C
    Semin Liver Dis; 2016 Feb; 36(1):15-26. PubMed ID: 26870929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary biliary cirrhosis and ursodeoxycholic acid therapy].
    Makino I
    Nihon Naika Gakkai Zasshi; 1996 Mar; 85(3):399-403. PubMed ID: 8691003
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients.
    Lammert C; Juran BD; Schlicht E; Chan LL; Atkinson EJ; de Andrade M; Lazaridis KN
    J Gastroenterol; 2014 Oct; 49(10):1414-20. PubMed ID: 24317935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
    Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre.
    Floreani A; Caroli D; Variola A; Rizzotto ER; Antoniazzi S; Chiaramonte M; Cazzagon N; Brombin C; Salmaso L; Baldo V
    Liver Int; 2011 Mar; 31(3):361-8. PubMed ID: 21059170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: a cause of resistance to ursodeoxycholic treatment.
    Floreani A; Baragiotta A; Guido M
    Dig Liver Dis; 2003 Feb; 35(2):128-9. PubMed ID: 12747633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.